文献速递消化系统肿瘤

血液生物标志物在局限性胰腺癌手术决策中的系统综述

The current role of blood-based biomarkers in surgical decision-making in patients with localised pancreatic cancer: A systematic review.
PubMed 文献 · Eur J Cancer · 2021-07-06

该系统综述检索至2019年10月的文献,纳入24项观察性研究共3367例胰腺腺癌患者,评估12种血液生物标志物对预测新辅助治疗反应、手术可切除性及术后早期复发的价值。CA19-9在多数研究中被报道,10项研究显示其可预测新辅助治疗反应和早期复发;CA125高于35 U/ml在两项研究中预测不可切除。但采样时机和截断值变异大,方法学异质性限制了临床应用。

要点

  • CA19-9可预测新辅助治疗反应和术后早期复发,但研究间采样时机和截断值差异显著。
  • CA125高于35 U/ml在两项研究中预测手术不可切除,证据有限。
  • 现有血液标志物因方法学异质性,辅助手术决策的价值受限,需标准化研究。

核心结论

  • 现有血液生物标志物在辅助局限性胰腺癌手术决策方面价值有限,主要受方法学异质性限制。

研究设计与样本

  • 系统综述检索MEDLINE/PubMed、Embase和Web of Science至2019年10月,纳入2000年1月至2019年9月发表、至少20例胰腺腺癌患者、报告至少一种血液标志物预测新辅助治疗反应、手术可切除性或术后早期复发的研究。

主要发现

  • 共识别2604项研究,最终纳入24项观察性研究,涵盖3367例患者和12种血液生物标志物。
  • CA19-9水平在多数研究中被报道,10项研究显示其可预测新辅助治疗反应和早期复发。
  • 两项研究显示CA125水平高于35 U/ml可预测手术不可切除。
  • 研究间采样时机和截断值存在显著变异。

关键数值与推荐

  • CA125高于35 U/ml在两项研究中预测手术不可切除。
  • CA19-9在10项研究中预测新辅助治疗反应和早期复发。

临床怎么用

  • CA19-9和CA125可作为局限性胰腺癌手术决策的参考,但需注意研究间采样时机和截断值的差异。
  • 目前证据尚不足以将血液生物标志物常规用于手术决策,需结合其他临床信息。

局限性

  • 所有纳入研究均为观察性研究。
  • 研究间采样时机和截断值存在显著变异,方法学异质性大。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The role of blood-based biomarkers in surgical decision-making in patients with localised pancreatic cancer remains unclear. This review aimed to report the utility of blood-based biomarkers focusing on prediction of response to neoadjuvant therapy, prediction of surgical resectability and early relapse after surgery. MATERIALS AND METHODS: MEDLINE/PubMed, Embase and Web of Science were searched till October 2019. Studies published between January 2000 and September 2019 with a minimum of 20 patients with pancreatic adenocarcinoma, reporting the utility of at least one blood-based biomarker in predicting response to neoadjuvant therapy and predicting surgical resectability or early relapse after surgery were included. RESULTS: A total of 2604 studies were identified, of which 24 comprising of 3367 patients and 12 blood-based biomarkers were included. All included studies were observational. Levels of carbohydrate antigen (CA)19-9 were reported in the majority of the studies. Levels of CA19-9 predicted the response to neoadjuvant therapy and early relapse in 10 studies. CA125 levels above 35 U/ml were predictive of surgical irresectability in two studies. However, marked variation in both timing of sampling and cut-off values was noted between studies. CONCLUSION: Despite some evidence of potential benefit, the utility of currently available blood-based biomarkers in aiding surgical decision-making in patients undergoing potentially curative treatment for pancreatic cancer is limited by methodological heterogeneity. Standardisation of future studies may allow a more comprehensive analysis of the biomarkers described in this review.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Diab HMH, Smith HG, Jensen KK, et al. The current role of blood-based biomarkers in surgical decision-making in patients with localised pancreatic cancer: A systematic review. Eur J Cancer. 2021. PMID: 34243080. doi:10.1016/j.ejca.2021.05.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。